Company: GEHC
Filing Date: 2025-04-30
Form Type: 10-Q
Source: 0001932393-25-000014
Chunk: 55

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-04-30
Form: 10-Q
Item: Item 1
Chunk 55
---
16)(14)Proceeds from stock issued under employee benefit plans20 16 Taxes paid related to net share settlement of equity awards(28)(11)All other financing activities – net(6)7 Cash from (used for) financing activities(286)(153)Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash27 (19)Increase (decrease) in cash, cash equivalents, and restricted cash(416)59 Cash, cash equivalents, and restricted cash at beginning of year2,893 2,506 Cash, cash equivalents, and restricted cash at end of period$2,476 $2,565 Supplemental disclosure of cash flows informationCash paid during the year for interest$(78)$(55)Non-cash investing activitiesAcquired but unpaid property, plant, and equipment$86 $53 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

8

Table of Contents                 

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION

GE HealthCare Technologies Inc. is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics.The condensed consolidated financial statements (the “financial statements”) of GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements. Operating results for the three months ended March 31, 2025 and 2024 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2024 period presented on the Condensed Consolidated Statement of Financial Position was derived from audited financial statements, but does not include all disclosures required